A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies
- Chan, A.
- Cameron, M.C.
- Garden, B.
- Boers-Doets, C.B.
- Schindler, K.
- Epstein, J.B.
- Choi, J.
- Beamer, L.
- Roeland, E.
- Russi, E.G.
- Bensadoun, R.J.
- Teo, Y.L.
- Chan, R.J.
- Shih, V.
- Bryce, J.
- Raber-Durlacher, J.
- Gerber, P.A.
- Freytes, C.O.
- Rapoport, B.
- LeBoeuf, N.
- Sibaud, V.
- Lacouture, M.E.
DOIAbstract
Purpose Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to ident...
Add to ORKG